# Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection

> **NCT04488575** · PHASE2 · TERMINATED · sponsor: **Evelo Biosciences, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** EDP1815
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04488575
- **Lead sponsor:** Evelo Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-26
- **Primary completion:** 2021-05-16
- **Final completion:** 2021-05-19
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Insufficient study defined patient population
- **Last updated:** 2022-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04488575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04488575, "Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04488575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*